The objective of this trial is to evaluate whether corifollitropin alfa (MK-8962, Org 36286) treatment for the induction of multifollicular growth in women undergoing Controlled Ovarian Stimulation (COS) prior to in vitro fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) is safe for pregnant participants and their offspring.
Age range
18 Years – 39 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Expectant Mothers Experiencing Adverse Events (AEs)
Timeframe: Up to 1 Year
Number of Expectant Mothers Experiencing Serious AEs (SAEs)
Timeframe: Up to 1 Year
Number of Infants Experiencing AEs
Timeframe: Up to 1 Year
Number of Infants Experiencing SAEs
Timeframe: Up to 1 Year
Take-Home Baby Rate
Timeframe: Birth of a one or more live babies (Up to 1 year)